- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
The post Pociredir, a Novel Oral Once-Daily Fetal Hemoglobin Inducer: Results from the Phase 1b PIONEER Study in Adult Participants with Severe Sickle Cell Disease and Hydroxyurea Intolerance or Unresponsiveness appeared first on Fulcrum Therapeutics.
The post FTX-6274, an EED Inhibitor, Demonstrates Robust Efficacy in Castration Resistant Prostate Cancer (CRPC) appeared first on Fulcrum Therapeutics.
The post Real-World Data Demonstrating the Correlation Between Increased Fetal Hemoglobin and Reduced VOC Rates in SCD appeared first on Fulcrum Therapeutics.
The post Pociredir, a Potent and Selective EED Inhibitor for the Treatment of Sickle Cell Disease, Induces Target Engagement and Gene Expression Changes that are Specific and Reversible in Wild-Type Mice appeared first on Fulcrum Therapeutics.
The post Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of the Novel Oral Fetal Hemoglobin (HbF) Inducer Pociredir in Healthy Adults in a Phase 1 Study appeared first on Fulcrum Therapeutics.
Jeff Statland, Angela Rosenbohm, Adolfo Lopez de Munain Arregui, Sabrina Sacconi, Doris G. Leung, Lawrence J. Hayward, Umesh A. Badrising, John Vissing, Nicol Voermans, Nuria Muelas, Benedikt Schoser, Leo Wang, Enrico Bugiardini, Hanns Lochmüller, Erin K. O’Ferrall, Henning Andersen, Johanna Hamel, Namita Goyal, Sankarsubramoney Subramony, Perry Shieh, Miriam Freimer, Elie Naddaf, Thomas Ragole, Lawrence Korngut, Teresinha Evangelista, Cornelia… The post Topline Efficacy and Safety Results From REACH: Phase 3 Placebo-Controlled Trial of Losmapimodfor Facioscapulohumeral Muscular Dystrophy (FSHD) appeared first on Fulcrum Therapeutics.
The post Losmapimod, a p38α/βMAPK inhibitor for the Potential Treatment of Patients with FSHD appeared first on Fulcrum Therapeutics.
The post An open-label pilot study of losmapimod to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments in participants with facioscapulohumeral muscular dystrophy type 1 appeared first on Fulcrum Therapeutics.
The post Facioscapulohumeral Muscular Dystrophy (FSHD) Disease Progression and Losmapimod Efficacy Assessed by Reachable Workspace in Both Arms appeared first on Fulcrum Therapeutics.
The post Interim Results of a Phase 1b Study (PIONEER) of an Oral HbF Inducer, Pociredir, in Sickle Cell Disease appeared first on Fulcrum Therapeutics.